Author

Caroline Labe

Institution: Blueprint Medicines (United States)

Observed institution: Blueprint Medicines (United States)

OpenAlex ID: A5093398579

Elenestinib, an Investigational, Next Generation KIT D816V Inhibitor, Reduces Mast Cell Burden, Improves Symptoms, and Has a Favorable Safety Profile in Patients with Indolent Systemic Mastocytosis: Analysis of the Harbor Trial

2023 · Tsewang Tashi, Olivier Hermine, et al. · Blood · 20

Works count: 1

Citation count: 20

H-index: 1

I10-index: 1